FindTrial
Sign In

Vincristine Liposomal

DRUG2 trials

Sponsors

ECOG-ACRIN Cancer Research Group, University of Southern California

Conditions

Acute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromeBlasts 5 Percent or More of Bone Marrow Nucleated CellsMyelodysplastic/Myeloproliferative NeoplasmPhiladelphia Chromosome PositiveRecurrent Acute Lymphoblastic LeukemiaRecurrent Adult Acute Myeloid LeukemiaRecurrent Adult Lymphoblastic LymphomaRecurrent B Acute Lymphoblastic Leukemia

Phase 1

Venetoclax and Vincristine in Treating Patients With Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia
Active, not recruitingNCT03504644
ECOG-ACRIN Cancer Research GroupRecurrent Adult Lymphoblastic Lymphoma, Recurrent B Acute Lymphoblastic Leukemia, Recurrent B Lymphoblastic Lymphoma +6
Start: 2018-08-13End: 2028-12-31Updated: 2026-08-07
EphB4-HSA Fusion Protein and Cytarabine /or Liposomal Vincristine in Patients With Recurrent or Refractory Acute Leukemia
TerminatedNCT03519984
University of Southern CaliforniaAcute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Blasts 5 Percent or More of Bone Marrow Nucleated Cells, Myelodysplastic/Myeloproliferative Neoplasm +8
Start: 2018-05-09End: 2020-11-24Updated: 2021-11-30

Related Papers

A phase 1 trial of venetoclax in combination with liposomal vincristine in patients with relapsed or refractory B‐cell or T‐cell acute lymphoblastic leukemia: Results from the ECOG‐ACRIN EA9152 protocol
eJHaem2024-08-083 citations
Maximal Tolerated Dose Determined for Venetoclax in Combination with Liposomal Vincristine in Patients with Relapsed or Refractory Ph-Negative T-Cell or B-Cell Acute Lymphoblastic Leukemia: Results of Phase 1 Portion of ECOG-ACRIN EA9152
Blood2021-11-057 citations